In gynecological cancers, particularly OCs and ECs, the activation of the KRAS pathway and the presence of KRAS mutations are substantial factors contributing to both de novo and acquired resistance against PI3K pathway inhibitors [43] (Table 2). This evidence concerns the gene KRAS and female reproductive organ cancer.